China is quietly taking control of US medicine. We must stop helping it.

The steady infiltration of China into the global pharmaceutical supply chain is no longer a distant threat but an accelerating reality, and the United States’ continued reliance on Chinese-made active pharmaceutical ingredients (APIs) and generic drugs is creating a dangerous dependency. While headlines focus on tariffs and trade wars, a quieter battle is being waged over who controls the lifeblood of modern medicine—raw materials, production lines, and the intellectual property that powers them. China has spent decades methodically dominating the upstream segments of the drug supply chain, from chemical synthesis to finished dosage forms, leveraging state subsidies, lax environmental oversight, and aggressive industrial policy to undercut competitors. The result is a situation where nearly half of all generic drugs in U.S. pharmacies rely on Chinese-made ingredients, and the country now supplies over 90% of certain antibiotics, vitamins, and critical care medications. This dependence is not merely an economic issue—it is a national security vulnerability. During the COVID-19 pandemic, supply chain disruptions revealed how quickly reliance on foreign manufacturing can paralyze healthcare systems. Yet even as tensions rise, U.S. policymakers have been slow to act. The FDA’s recent emphasis on strengthening inspections and diversifying supply chains marks a belated recognition of the problem, but regulatory frameworks remain fragmented and underfunded. Meanwhile, Chinese pharmaceutical firms, often state-backed or closely aligned with Beijing, continue to acquire critical assets abroad, including key API producers in India and Europe, further embedding China’s control over global production networks. The path forward is fraught with challenges. Rebuilding domestic capacity in generic and essential drug manufacturing will require substantial investment, tax incentives, and possibly even temporary protectionist measures to shield fledgling industries from predatory pricing. It also demands a reevaluation of how pharmaceutical innovation is incentivized—shifting focus from blockbuster drugs to the mundane but vital generic medicines that keep hospitals and clinics running. Without decisive action, the U.S. risks ceding not just economic leadership in biopharmaceuticals but the very ability to ensure its citizens have access to affordable, reliable medicines when crises strike. The question is not whether China will weaponize its dominance, but when—and whether the U.S. will act in time.